TNFSF10 and malignant colon neoplasm: These findings support the impact that this therapy, and that the elucidated mechanism, may have on the treatment of our patients with colon cancer and on the other TRAIL-resistant solid organ gastrointestinal malignancies that we tested, especially since the safety profile and lack of toxicity of both 2DG and TRAIL have been established in multiple human trials.6,8,13,14,29,30